Suppr超能文献

药品监管的理念——家长式管理还是选择自由?

The philosophy of pharmaceutical regulation-Paternalism or freedom of choice?

作者信息

Mahlich Jörg, Riou Sybille, Verry Matthieu

机构信息

Miltenyi Biomedicine, Bergisch Gladbach, Germany.

Düsseldorf Institute for Competition Economics (DICE), Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.

出版信息

Front Med (Lausanne). 2023 Oct 27;10:1264021. doi: 10.3389/fmed.2023.1264021. eCollection 2023.

Abstract

When assessing the value of new drugs regulatory authorities across the world frequently make different decisions even though their decisions are based on the same evidence package. In this perspective we argue that even in today's world regulatory and medical decision making is framed by conflicting philosophical schools of thought, namely the liberal tradition of the Anglo Saxon countries pioneered by the Scotsman Adam Smith and the continental European tradition of paternalism that roots back to the German philosopher Georg Friedrich Hegel. We outline the basics of these two philosophical theories and show that countries following the liberal tradition are more reluctant to reject new drugs due to weak evidence. Instead, they leave decisions to a greater extend to those who are affected, namely patients and their caregivers.

摘要

在评估新药价值时,尽管世界各地的监管机构依据相同的证据做出决策,但它们常常会做出不同的决定。从这个角度来看,我们认为,即使在当今世界,监管决策和医疗决策也受到相互冲突的哲学思想流派的影响,即由苏格兰人亚当·斯密开创的盎格鲁-撒克逊国家的自由主义传统,以及可追溯到德国哲学家格奥尔格·弗里德里希·黑格尔的欧洲大陆家长式统治传统。我们概述了这两种哲学理论的基本要点,并表明遵循自由主义传统的国家不太愿意因证据不足而拒绝新药。相反,它们在更大程度上把决策权交给受影响的人,即患者及其护理人员。

相似文献

1
The philosophy of pharmaceutical regulation-Paternalism or freedom of choice?
Front Med (Lausanne). 2023 Oct 27;10:1264021. doi: 10.3389/fmed.2023.1264021. eCollection 2023.
2
Gadamerian dialogue in the patient-professional interaction.
Med Health Care Philos. 2000;3(1):17-23. doi: 10.1023/a:1009908132170.
3
Autonomy, liberalism and advance care planning.
J Med Ethics. 1999 Dec;25(6):522-7. doi: 10.1136/jme.25.6.522.
4
Liberal rationalism and medical decision-making.
Bioethics. 1997 Apr;11(2):115-29. doi: 10.1111/1467-8519.00049.
7
On Nudging's Supposed Threat to Rational Decision-Making.
J Med Philos. 2019 Jul 29;44(4):403-422. doi: 10.1093/jmp/jhz014.
8
The theorisation of 'best interests' in bioethical accounts of decision-making.
BMC Med Ethics. 2021 Jun 1;22(1):68. doi: 10.1186/s12910-021-00636-0.
9
[The origin of informed consent].
Acta Otorhinolaryngol Ital. 2005 Oct;25(5):312-27.
10
Invisible hand or fatherly hand? Problems of paternalism in the New Perspective on health.
J Health Polit Policy Law. 1983 Winter;7(4):784-807. doi: 10.1215/03616878-7-4-784.

本文引用的文献

1
HTA decision-making for drugs for rare diseases: comparison of processes across countries.
Orphanet J Rare Dis. 2022 Jul 8;17(1):258. doi: 10.1186/s13023-022-02397-4.
2
Bright line or lottery? On significance and value in medical decision making.
J Mark Access Health Policy. 2021 Sep 20;9(1):1981574. doi: 10.1080/20016689.2021.1981574. eCollection 2021.
3
Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials.
Value Health. 2021 Aug;24(8):1118-1125. doi: 10.1016/j.jval.2021.01.015. Epub 2021 Jun 8.
4
The Evaluation of Orphan Drugs by the German Joint Federal Committee-An Eight-Year Review.
Dtsch Arztebl Int. 2020 Dec 11;117(50):868-869. doi: 10.3238/arztebl.2020.0868.
5
Single-arm Trials With External Comparators and Confounder Misclassification: How Adjustment Can Fail.
Med Care. 2020 Dec;58(12):1116-1121. doi: 10.1097/MLR.0000000000001400.
8
The Role of Noncomparative Evidence in Health Technology Assessment Decisions.
Value Health. 2017 Dec;20(10):1245-1251. doi: 10.1016/j.jval.2017.06.015. Epub 2017 Sep 12.
9
Using Discrete Choice Experiments to Inform the Benefit-Risk Assessment of Medicines: Are We Ready Yet?
Pharmacoeconomics. 2017 Sep;35(9):859-866. doi: 10.1007/s40273-017-0518-0.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验